Flare Therapeutics

Flare Therapeutics develops small molecule medicines by studying the biology of transcription factors.

The Flare Therapeutics website provides information about the company. Its privacy policy describes its policy regarding information, including personally identifiable data.

Flare Therapeutics closes an $85 million Series C financing led by existing investors Third Rock Ventures and Nextech Invest, and appoints Anna Protopapas as chief executive officer. The financing also includes Pfizer Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly, Novartis, Agent Capital, and Eventide Asset Management; proceeds will fund advancement of the company’s ARON degrader FX-111 toward clinical development.

Jun 2026 · Flare TherapeuticsNews article

Flare Therapeutics appoints Stephen L. Eck, M.D., Ph.D., as chief medical officer, effective January 2026. Eck previously served as senior vice president of clinical development and chief medical officer at MacroGenics and held oncology drug development leadership roles at Astellas, Eli Lilly, and Pfizer. He succeeds Michael L. Meyers, who retired from the role.

Jan 2026 · Flare TherapeuticsNews article

Flare Therapeutics presents correlative biomarker analysis from its FX-909 Phase 1A clinical study at the SITC 2025 40th Anniversary Annual Meeting. The data support a planned Phase 1 cohort testing FX-909 with pembrolizumab in metastatic urothelial cancer, with initiation planned for the first quarter of 2026.

Nov 2025 · Flare TherapeuticsNews article

Flare Therapeutics announces a strategic discovery collaboration with Roche to discover and develop small-molecule drugs against previously undrugged transcription factor targets in oncology. For the collaboration, Roche contributes oncology development capabilities, while Flare brings its switch-site transcription factor drug discovery platform.

Nov 2024 · Flare TherapeuticsNews article